Streetwise Reports' Article Archives — Current Month (21)

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation (01/16/2020)

Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously.


Biotech Announces Deal with Bayer on Non-Hormonal Contraception (01/15/2020)

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report.


Disruptive Technology Poised to Deliver Significant Advancement in Bladder Cancer Detection (01/14/2020)

Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy.


Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer Detection and Surgery (01/14/2020)

The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.'


Healthcare Company Closes Acquisition of Telehealth Firm (01/14/2020)

The transaction brings numerous existing partnerships and digital technologies.


Transenterix Shares Trade Up 25% on FDA Filing for First Machine Vision System in Robotic Surgery (01/14/2020)

Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery.


Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications (01/13/2020)

Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications.


Telemedicine Tech Firm Garners Five New US Clients (01/10/2020)

With these contracts, the company extends its geographic footprint to an additional county.


Life Sciences Firm Upgrades to OTCQB Venture Market (01/10/2020)

This is a significant achievement of this developing company.


Developer Completes Design Verification of Imaging Device for Bladder Cancer (01/10/2020)

In doing so, it gets one step closer to market approval from U.S. regulators.


Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study (01/10/2020)

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency.


Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results (01/09/2020)

Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020.


Developer of Oncology Therapeutics to Have 'Catalyst Rich' 2020 (01/08/2020)

The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report.


Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study (01/08/2020)

Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20.


Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial (01/07/2020)

Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria.


Kyorin's $175M Partnership Offers Good Life for aTyr Pharma in Japan (01/06/2020)

aTyr Pharma's shares traded 45% higher today after the firm reported that it had entered into a collaboration agreement with Kyorin Pharmaceutical for development and commercialization of its ATYR1923 drug in Japan.


Biopharma's Migraine Phase 3 Trial Results 'Robust,' 'Impressive' (01/03/2020)

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report.


Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder (01/03/2020)

The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report.


Biopharma Releases Topline Results from Psoriasis Trial (01/03/2020)

The company, however, will continue to advance the same therapeutic in two other diseases.


Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise (01/03/2020)

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity financing from BeiGene and two other investment groups.


Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100% (01/02/2020)

Pulmatrix's shares opened 90% higher today after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson.


More Archives


2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes